Plerixafor and Filgrastim XM02 (Tevagastrim ®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation

摘要: Plerixafor, a CXCR4 antagonist, has shown to be effective in increasing the number of circulating stem cells, even patients failing previous mobilisation attempt. Recently non-glycosylated recombinant human granulocyte-colony stimulating factor (G-CSF) been clinically approved for same indications as originator G-CSF comparable safety and efficacy their reduced cost. In an attempt provide less toxic strategy, 14 affected by haematological malignancies (non-Hodgkin's lymphoma = 4, Hodgkin's disease 2 multiple myeloma 8), received combination biosimilar filgrastim plerixafor first line mobilising strategy. The median CD34+ cells on day 4 was 16 (3-42); Plerixafor administered all, but one patient who had already 42 per μL 4. On 5, after administration, raised 60 (14-138). All underwent leukapheresis were able collect ≥ 2.0 × 10(6) /kg procedures one. Although preliminary, these data show is provides non-toxic approach mobilise cells.